Breast Cancer Research and Treatment

, Volume 122, Issue 1, pp 9–10 | Cite as

Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint

Invited Commentary


Breast Cancer Overall Survival Paclitaxel Bevacizumab Trastuzumab 


  1. 1.
    Miller K, Wand D, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NA (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Eng J Med 357:2666–2676CrossRefGoogle Scholar
  2. 2.
    Pivot X, Verma S, Thomssen C, Passos-Coelho JL, Latini L, Ciruelos R, Silva M, von Moss R, Chang H, Miles DW (2009) Clinical benefit of bevacizumab plus first-line docetaxel in elderly patients with locally recurrent or metastatic breast cancer. J Clin Oncol 27:15s (abstract 1094)CrossRefGoogle Scholar
  3. 3.
    Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov Om Perez E, Yardley E, Zhou X, Phan S (2009) RIBBON-1: randomized, double blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 27:15s (abstract 1005)CrossRefGoogle Scholar
  4. 4.
    Saad ED, Katz A, Hoff PM, Buyse M (2010) Progression-free survival as surrogate and as true end point: insights from breast and colorectal cancer literature. Ann Oncol 21:7–12CrossRefPubMedGoogle Scholar
  5. 5.
    Slamon DJ, Leyland-Jones ShakS, Fuchs H, Patton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344:783–792CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  1. 1.Fairfax Northern VA Fairfax USA

Personalised recommendations